Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial

Hess, Viviane; Salzberg, Marc; Borner, Markus; Morant, Rudolf; Roth, Arnaud; Ludwig, Christian; Herrmann, Richard

Scientific article

English

Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial

ContributorsHess, Viviane; Salzberg, Marc; Borner, Markus; Morant, Rudolf; Roth, Arnaud; Ludwig, Christian; Herrmann, Richard

Published inJournal of clinical oncology, vol. 21, no. 1, p. 66-68

Publication date2003

Abstract

Preclinical studies indicate positive interactions between capecitabine, an oral fluorouracil precursor, and gemcitabine, the current standard treatment for advanced pancreatic carcinoma (APC). In this study, we investigated the addition of capecitabine to gemcitabine treatment for patients with APC.

Keywords

Aged
Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
Deoxycytidine/administration & dosage/adverse effects/analogs & derivatives
Female
Fluorouracil/analogs & derivatives
Humans
Male
Maximum Tolerated Dose
Middle Aged
Pancreatic Neoplasms/drug therapy/mortality
Survival Rate
Switzerland/epidemiology

Affiliation

Research group

Groupe Roth Arnaud (oncologie) (285)

Citation (ISO format)

HESS, Viviane et al. Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial. In: Journal of clinical oncology, 2003, vol. 21, n° 1, p. 66–68.

Article (Published version)

Identifiers

PID : unige:45240
PMID : 12506172

Commercial URLhttp://jco.ascopubs.org/content/21/1/66.long

ISSN of the journal0732-183X

465views

0downloads

Creation01/13/2015 1:04:00 PM

First validation01/13/2015 1:04:00 PM

Update time03/14/2023 10:41:21 PM

Status update03/14/2023 10:41:21 PM

Last indexation01/16/2024 3:53:05 PM

Archive ouverte UNIGE

Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial

Technical informations